Skip to main content

Advertisement

SpringerLink
Log in

Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

Improved survival for men with prostate cancer has led to increased attention to factors influencing quality of life (QOL). As protein levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) have been reported to be associated with QOL in people with cancer, we sought to identify whether single-nucleotide polymorphisms (SNPs) of these genes were associated with QOL in men with prostate cancer.

Methods

Multiple linear regression of two data sets (including approximately 750 men newly diagnosed with prostate cancer and 550 men from the general population) was used to investigate SNPs of VEGF and IGF-1 (10 SNPs in total) for associations with QOL (measured by the SF-36v2 health survey).

Results

Men with prostate cancer who carried the minor ‘T’ allele for IGF-1 SNP rs35767 had higher mean Role-Physical scale scores (≥0.3 SD) compared to non-carriers (p < 0.05). While this association was not identified in men from the general population, one IGF-1 SNP rs7965399 was associated with higher mean Bodily Pain scale scores in men from the general population that was not found in men with prostate cancer. Men from the general population who carried the rare ‘C’ allele had higher mean Bodily Pain scale scores (≥0.3 SD) than non-carriers (p < 0.05).

Conclusions

Through identifying SNPs that are associated with QOL in men with prostate cancer and men from the general population, this study adds to the mapping of complex interrelationships that influence QOL and suggests a role for IGF-I in physical QOL outcomes. Future research may identify biomarkers associated with increased risk of poor QOL that could assist in the provision of pre-emptive support for those identified at risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Namiki, S., & Arai, Y. (2010). Health-related quality of life in men with localized prostate cancer. International Journal of Urology, 17(2), 125–138.

    Article  PubMed  Google Scholar 

  2. Romeis, J. C., Heath, A. C., Xian, H., Eisen, S. A., Scherrer, J. F., Pedersen, N. L., et al. (2005). Heritability of SF-36 among middle-age, middle-class, male–male twins. Medical Care, 43(11), 1147–1154.

    Article  PubMed  Google Scholar 

  3. Romeis, J. C., Scherrer, J. F., Xian, H., Eisen, S. A., Bucholz, K., Heath, A. C., et al. (2000). Heritability of self-reported health. Health Services Research, 35(5 Pt 1), 995–1010.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Nes, R. B., Roysamb, E., Tambs, K., Harris, J. R., & Reichborn-Kjennerud, T. (2006). Subjective well-being: Genetic and environmental contributions to stability and change. Psychological Medicine, 36(7), 1033–1042.

    Article  CAS  PubMed  Google Scholar 

  5. Sprangers, M. A., Sloan, J. A., Veenhoven, R., Cleeland, C. S., Halyard, M. Y., Abertnethy, A. P., et al. (2009). The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Research and Human Genetics, 12(3), 301–311.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Sprangers, M. A., Sloan, J. A., Barsevick, A., Chauhan, C., Dueck, A. C., Raat, H., et al. (2010). Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Quality of Life Research, 19(10), 1395–1403.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Sprangers, M. A. G., Thong, M. S. Y., Bartels, M., Barsevick, A., Ordoñana, J., Shi, Q., et al. (2014). Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: An update. Quality of Life Research, 23(7), 1997–2013.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Miaskowski, C., & Aouizerat, B. E. (2012). Biomarkers: Symptoms, survivorship, and quality of life. Seminars in Oncology Nursing, 28(2), 129–138.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Peters, C. A., Stock, R. G., Cesaretti, J. A., Atencio, D. P., Peters, S., Burri, R. J., et al. (2008). TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. International Journal of Radiation Oncology Biology Physics, 70(3), 752–759.

    Article  CAS  Google Scholar 

  10. Langsenlehner, T., Renner, W., Gerger, A., Hofmann, G., Thurner, E. M., Kapp, K. S., et al. (2011). Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlentherapie und Onkologie, 187(12), 784–791.

    Article  PubMed  Google Scholar 

  11. De Langhe, S., De Ruyck, K., Ost, P., Fonteyne, V., Werbrouck, J., De Meerleer, G., et al. (2013). Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFbeta1 gene. International Journal of Radiation Oncology Biology Physics, 85(2), 393–399.

    Article  Google Scholar 

  12. Langsenlehner, T., Thurner, E. M., Krenn-Pilko, S., Gerger, A., & Langsenlehner, U. (2012). Genetic prediction of radiation-induced morbidity in prostate cancer patients. Radiotherapy and Oncology, 105(3), 380–381.

    Article  PubMed  Google Scholar 

  13. Djavan, B., Waldert, M., Seitz, C., & Marberger, M. (2001). Insulin-like growth factors and prostate cancer. World Journal of Urology, 19(4), 225–233.

    Article  CAS  PubMed  Google Scholar 

  14. van Moorselaar, R. J., & Voest, E. E. (2002). Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches. Molecular and Cellular Endocrinology, 197(1–2), 239–250.

    Article  PubMed  Google Scholar 

  15. Lutgendorf, S. K., Johnsen, E. L., Cooper, B., Anderson, B., Sorosky, J. I., Buller, R. E., et al. (2002). Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 95(4), 808–815.

    Article  CAS  PubMed  Google Scholar 

  16. Meyerhardt, J. A., Sloan, J. A., Sargent, D. J., Goldberg, R. M., Pollak, M., Morton, R. F., et al. (2005). Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention, 14(6), 1402–1410.

    Article  CAS  PubMed  Google Scholar 

  17. Hinds, D. A., Stuve, L. L., Nilsen, G. B., Halperin, E., Eskin, E., Ballinger, D. G., et al. (2005). Whole-genome patterns of common DNA variation in three human populations. Science, 307(5712), 1072–1079.

    Article  CAS  PubMed  Google Scholar 

  18. Baade, P. D., Aitken, J. F., Ferguson, M., Gardiner, R. A., & Chambers, S. K. (2010). Diagnostic and treatment pathways for men with prostate cancer in Queensland: Investigating spatial and demographic inequalities. BMC Cancer, 10, 452.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Lose, F., Batra, J., O’Mara, T., Fahey, P., Marquart, L., Eeles, R. A., et al. (2013). Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology, 31(5), 635–643.

    Article  CAS  PubMed  Google Scholar 

  20. Batra, J., Lose, F., O’Mara, T., Marquart, L., Stephens, C., Alexander, K., et al. (2011). Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS ONE, 6(11), e26527.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Health Assessment Lab - Medical Outcomes Trust and QualityMetric Incorporated (2003). SF-36v2 Health Survey, IQOLA SF36v2 Standard, English (Australia).

  22. Fayers, P., & Machin, D. (2007). Quality of life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes (Vol. Book, Whole): Wiley.

    Book  Google Scholar 

  23. Sommers, S. D., & Ramsey, S. D. (1999). A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics, 16(2), 127–140.

    Article  CAS  PubMed  Google Scholar 

  24. Hawthorne, G., Osborne, R. H., Taylor, A., & Sansoni, J. (2007). The SF36 Version 2: Critical analyses of population weights, scoring algorithms and population norms. Quality of Life Research, 16(4), 661–673.

    Article  PubMed  Google Scholar 

  25. Ware, J. E., Kosinski, M., Bjorner, J., Turner-Bowker, D., Gandek, B., & Maruish, M. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln: QualityMetric.

    Google Scholar 

  26. Lose, F., Nagle, C. M., O’Mara, T., Batra, J., Bolton, K. L., Song, H., et al. (2010). Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecologic Oncolology, 119(3), 479–483.

    Article  CAS  Google Scholar 

  27. Cheng, I., Stram, D. O., Penney, K. L., Pike, M., Le Marchand, L., Kolonel, L. N., et al. (2006). Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. Journal of the National Cancer Institute, 98(2), 123–134.

    Article  CAS  PubMed  Google Scholar 

  28. Rothman, K. J. (1990). No adjustments are needed for multiple comparisons. Epidemiology, 1(1), 43–46.

    Article  CAS  PubMed  Google Scholar 

  29. Hattersley, A. T., & McCarthy, M. I. (2005). What makes a good genetic association study? Lancet, 366(9493), 1315–1323.

    Article  PubMed  Google Scholar 

  30. Edge, S. B., & American Joint Committee on, C. (2010). AJCC cancer staging manual (Vol. Book, Whole). New York: Springer.

  31. Elis, S., Wu, Y., Courtland, H. W., Cannata, D., Sun, H., Beth-On, M., et al. (2011). Unbound (bioavailable) IGF1 enhances somatic growth. Disease Models and Mechanisms, 4(5), 649–658.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Palles, C., Johnson, N., Coupland, B., Taylor, C., Carvajal, J., Holly, J., et al. (2008). Identification of genetic variants that influence circulating IGF1 levels: A targeted search strategy. Human Molecular Genetics, 17(10), 1457–1464.

    Article  CAS  PubMed  Google Scholar 

  33. Patel, A. V., Cheng, I., Canzian, F., Le Marchand, L., Thun, M. J., Berg, C. D., et al. (2008). IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE, 3(7), e2578.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Kostek, M. C., Devaney, J. M., Gordish-Dressman, H., Harris, T. B., Thompson, P. D., Clarkson, P. M., et al. (2010). A polymorphism near IGF1 is associated with body composition and muscle function in women from the health, aging, and body composition study. European Journal of Applied Physiology, 110(2), 315–324.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Ben-Zaken, S., Meckel, Y., Nemet, D., & Eliakim, A. (2013). Can IGF-I polymorphism affect power and endurance athletic performance? Growth Hormone & IGF Research, 23(5), 175–178.

    Article  CAS  Google Scholar 

  36. Qian, B., Zheng, H., Yu, H., & Chen, K. (2011). Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research and Treatment, 130(1), 217–226.

    Article  CAS  PubMed  Google Scholar 

  37. Hernandez, W., Grenade, C., Santos, E. R., Bonilla, C., Ahaghotu, C., & Kittles, R. A. (2007). IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis, 28(10), 2154–2159.

    Article  CAS  PubMed  Google Scholar 

  38. Cuatrecasas, G., Alegre, C., & Casanueva, F. F. (2014). GH/IGF1 axis disturbances in the fibromyalgia syndrome: Is there a rationale for GH treatment? Pituitary, 17(3), 277–283.

    Article  CAS  PubMed  Google Scholar 

  39. Morgado, C., Silva, L., Pereira-Terra, P., & Tavares, I. (2011). Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: The preventive action of IGF1. Neurobiology of Disease, 43(1), 275–284.

    Article  CAS  PubMed  Google Scholar 

  40. Miaskowski, C., Cooper, B. A., Melisko, M., Chen, L. M., Mastick, J., West, C., et al. (2014). Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer, 120(15), 2371–2378.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Staff, I., Salner, A., Bohannon, R., Panatieri, P., & Maljanian, R. (2003). Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy. Cancer, 98(11), 2335–2343.

    Article  PubMed  Google Scholar 

  42. Clark, J. A., Rieker, P., Propert, K. J., & Talcott, J. A. (1999). Changes in quality of life following treatment for early prostate cancer. Urology, 53(1), 161–168.

    Article  CAS  PubMed  Google Scholar 

  43. Baumeister, H., Kriston, L., Bengel, J., & Harter, M. (2010). High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. Journal of Clinical Epidemiology, 63(5), 558–565.

    Article  PubMed  Google Scholar 

  44. Schwartz, C. E., & Sprangers, M. A. (1999). Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Social Science and Medicine, 48(11), 1531–1548.

    Article  CAS  PubMed  Google Scholar 

  45. Korfage, I. J., Hak, T., de Koning, H. J., & Essink-Bot, M. L. (2006). Patients’ perceptions of the side-effects of prostate cancer treatment—a qualitative interview study. Social Science and Medicine, 63(4), 911–919.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank the many patients and control subjects for participating; the great contribution made by Diana Battistutta to this project; the members of the Cancer Council Queensland, particularly Megan Ferguson and Andrea Kittila; the hospitals that participated in recruitment for the ProsCan study: Greenslopes Private, Royal Brisbane, Mater Adults, Princess Alexandra, Ipswich, QEII, Redlands and Redcliffe Hospitals, Townsville General Hospital and Mackay Base Hospital; the QUT Prostate Cancer Program, particularly Patricia Vanden Bergh, Soulmaz Rostami, Naomi Richardson and Robert Smith, members from the QIMR Berghofer Molecular Cancer Epidemiology Laboratory and XiaoQing Chen and Jonathan Beesley from QIMR Berghofer. This research was funded by National Health and Medical Research Council (NHMRC) Grants 390130, 290456, 614296, 1009458. A number of authors are supported by NHMRC fellowships (J. Clements: NHMRC Principal Research Fellowship, M. Spurdle: NHMRC Senior Research Fellowship, J. Batra: NHMRC Early Career Fellowship and Institute of Health and Biomedical Innovation (IHBI) Fellowship and F. Lose: PCFA Funding, S. Chambers: NHMRC Career Development Award). K. Alexander was supported by an Australian Postgraduate Award and T. O’Mara was supported by an Australian Postgraduate Award, Queensland Government PhD Award and IHBI PhD Award.

Conflict of interest

The authors declare they have no conflict of interest.

Ethical Standards

The authors declare that the above research was approved by the Queensland University of Technology (QUT), QIMR Berghofer Medical Research Institute, Mater Hospital (for Brisbane Private Hospital), Royal Brisbane Hospital, Princess Alexandra Hospital and the Cancer Council Queensland Human Research Ethics Committees. All participants gave informed consent prior to the inclusion in this study.

Author information

Authors and Affiliations

  1. Institute of Health and Biomedical Innovation (IHBI), School of Nursing, Queensland University of Technology (QUT), Kelvin Grove, Brisbane, QLD, 4059, Australia

    Kimberly E. Alexander

  2. Griffith Health Institute, Griffith University, Gold Coast, QLD, Australia

    Suzanne Chambers

  3. Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD, Australia

    Jyotsna Batra, Judith A. Clements & Mary-Anne Kedda

  4. Molecular Cancer Epidemiology Group, Genetics and Population Health Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

    Amanda B. Spurdle, Felicity Lose & Tracy A. O’Mara

  5. Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia

    Robert A. Gardiner

  6. Viertel Centre for Cancer Research, Cancer Council Queensland, Brisbane, QLD, Australia

    Joanne F. Aitken

  7. Institute of Health and Biomedical Innovation (IHBI), School of Public Health and Social Work, Queensland University of Technology (QUT), Brisbane, QLD, Australia

    Monika Janda

  8. Department of Urology, Royal Brisbane & Women’s Hospital, Brisbane, QLD, Australia

    Robert A. Gardiner

Authors
  1. Kimberly E. Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzanne Chambers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amanda B. Spurdle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jyotsna Batra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Felicity Lose
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tracy A. O’Mara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert A. Gardiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joanne F. Aitken
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Judith A. Clements
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mary-Anne Kedda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Monika Janda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimberly E. Alexander.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alexander, K.E., Chambers, S., Spurdle, A.B. et al. Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population. Qual Life Res 24, 2183–2193 (2015). https://doi.org/10.1007/s11136-015-0950-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-015-0950-6

Keywords

Search

Navigation